List view / Grid view

Articles

 

21st Anniversary Supplement

21 December 2017 | By

European Pharmaceutical Review has brought you the most up-to-date and relevant pharmaceutical science for the past 21 years. This anniversary supplement brings you a selection of topical views from across the industry, reviewing progress over that time, as well as looking to the future.

The impact of Brexit on life sciences

19 December 2017 | By ,

On 30 March 2019 the UK is set to leave the European Union (EU), a process that has become popularly known as Brexit. One little talked-about aspect of this move in the mainstream media is the impact it will have on the British life science community. Researchers and industry leaders…

What do we need from PAT?

18 December 2017 | By ,

Pharmaceutical manufacturing in the modern era is facing unprecedented demands, including in-depth scrutiny of production methodology, and inefficiencies in current practices with respect to waste, energy usage and time management. Coupling this with increased complexity in the manufacture of newer products and the decline of blockbuster drugs, results in an…

Photobleaching profile of Raman peaks and fluorescence background

15 December 2017 | By , , , ,

Laser-induced fluorescence is the most common source of interfering baseline signal encountered in Raman measurements. It shows itself as a slowly changing background in a spectrum. One of the challenges in the successful use of Raman spectroscopy is to extract Raman signatures from this, orders of magnitude stronger, broadband fluorescence…

Non-clinical dose formulation considerations

15 December 2017 | By

Designing appropriate non-clinical safety studies requires thoughtful, and sometimes experimental, consideration of the delivery methodology for the therapeutic. The choice of formulation affects drug release and absorption and has a direct impact on the pharmacokinetic profile and associated response of the model system. The formulation should be compatible with the…

Improving patient access, the UCB way

23 November 2017 | By

UCB’s ambition, according to its website, is to transform the lives of people living with severe diseases. The company’s Head of Global Clinical Development and Medical Affairs Stuart Dollow believes that making its clinical trial design more patient-centred and creating the right partnerships are key steps toward improving access to…

Send this to a friend